Company Description
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs.
The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases.
The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses.
Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
| Country | Israel |
| Founded | 2010 |
| IPO Date | Jun 28, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Ms. Miranda J. Toledano M.B.A. |
Contact Details
Address: Kiryat Hadassah, Minrav Building, Fifth Floor Jerusalem, L3 9112002 Israel | |
| Phone | 972-2-532-7151 |
| Website | enterabio.com |
Stock Details
| Ticker Symbol | ENTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001638097 |
| CUSIP Number | M40527109 |
| ISIN Number | IL0011429839 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Miranda J. Toledano M.B.A. | Chief Executive Officer and Director |
| Dana Yaacov-Garbeli CPA | Chief Financial Officer |
| Dr. Hillel Galitzer M.B.A., Ph.D. | Chief Operating Officer |
| Dr. Arthur C. Santora II, M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 8, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 8, 2024 | 10-K | Annual Report |
| Mar 8, 2024 | 8-K | Current Report |
| Mar 4, 2024 | 8-K | Current Report |
| Feb 15, 2024 | 424B3 | Prospectus |
| Feb 14, 2024 | EFFECT | Notice of Effectiveness |
| Feb 14, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Feb 2, 2024 | 8-K | Current Report |
| Feb 2, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 16, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |